Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin.

Abstract

Based on our wide ranging knowledge of phosphoramidate ProTides as anti-viral agents we have tuned the lead anti-cancer agent thymectacin in the ester and amino acid regions and revealed a substantial enhancement in in vitro potency versus colon and prostate cancer cell lines. Twelve analogues have been reported, with yields of 29-78%. The compounds are fully characterised and data clearly reveal the presence of two phosphate diastereoisomers, as expected, in roughly equi-molar proportions. The compounds were evaluated in tissue culture versus three different tumour cell lines, using thymectacin as the control. It is notable that minor structural modification of the parent phenyl methoxyalaninyl structure of thymectacin leads to significant enhancements in potency. In particular, replacement of the methyl ester moiety in the lead by a benzyl ester gave a 175-fold boost in potency versus colon cancer HT115. This derivative emerges as a low micromolar inhibitor of HT115 cells and a new lead for further optimisation.

• Authors: Christopher McGuigan, Jean-Christophe Thiery, Felice Daverio, Wen G Jiang, Gaynor Davies, Malcolm Mason
• Journal: Bioorganic & medicinal chemistry (Bioorg Med Chem) Vol. 13 Issue 9 Pg. 3219-27 (May 02 2005) ISSN: 0968-0896 [Print] England
• PMID: 15809157 (Publication Type: Journal Article)

Chemical References

• Amides
• Antineoplastic Agents
• Phosphoric Acids
• thymectacin
• phosphoramidic acid
• Bromodeoxyuridine

Topics

• Amides (chemical synthesis, chemistry, pharmacology)
• Antineoplastic Agents (chemical synthesis, chemistry, pharmacology)
• Bromodeoxyuridine (analogs & derivatives, chemical synthesis, pharmacology)
• Cell Line, Tumor
• Cell Survival (drug effects)
• Drug Screening Assays, Antitumor
• Humans
• Molecular Conformation
• Phosphoric Acids (chemical synthesis, chemistry, pharmacology)
• Stereoisomerism
• Structure-Activity Relationship